Avidity’s early-phase data for rare muscle disease drug spur registrational plans

Avidity Biosciences’ antibody oligonucleotide conjugate has shown signs of efficacy in an early-stage test in patients with a rare muscle-wasting disease.

Just last month, Leerink …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novartis CEO plays down Cytokinetics buyout rumors in CNBC interview

Novartis CEO Vas Narasimhan threw cold water on the rumors about his company’s potential acquisition of the biotech Cytokinetics. In an interview on CNBC, Narasimhan

January 10, 2024

Denmark study: Air pollution tied to increased risk of dementia

This is the first study in Denmark showing a link between air pollution and dementia.

May 17, 2024

Platelets quell the inflammation of an aging brain and body: Study finds

Platelets are behind the cognitive benefits of young blood, exercise and the longevity hormone klotho

August 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.